Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of S. flexneri 2a-S. sonnei Bivalent Conjugate Vaccine in Children
NCT05156528Phase 3Unknown
- Sponsor
- Zhifei Green Bamboo
- Start
- Dec 2021
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Shigella flexneri-sonnei bivalent conjugate vaccine in shigellosis (2 arms), sponsored by Zhifei Green Bamboo. Primary endpoint: Efficacy study assessed by protective rate. Status: unknown.
02
Drugs
Shigella flexneri-sonnei bivalent conjugate vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT05156528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156528.